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Abstract: Colorectal cancer (CRC) is the third most common epithelial malignancy in the 
world. Since CRC develops slowly from removable precancerous lesions, detection of the 
lesion  at  an  early  stage  by  regular  health  examinations  can  reduce  the  incidence  and 
mortality  of  this  malignancy.  Colonoscopy  significantly  improves  the  detection  rate  of 
CRC,  but  the  examination  is  expensive  and  inconvenient.  Therefore,  we  need  novel 
biomarkers that are non-invasive to enable us to detect CRC quite early. A number of 
validation studies have been conducted to evaluate genetic, epigenetic or protein markers 
for identification in the stool and/or serum. Currently, the fecal occult blood test is the most 
widely  used  method  of  screening  for  CRC.  However,  advances  in  genomics  and 
proteomics will lead to the discovery of novel non-invasive biomarkers. 
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1.  Introduction  
Various types of cancer biomarkers are listed in Table 1.  
Table 1. Cancer biomarkers. 
Type of biomarkers  Analysis 
Genetic 
Gene mutations 
Tumor suppressor gene status 
DNA 
Gene amplification 
Microsatellite instability 
Mitochondrial DNA 
Epigenetic  DNA methylation 
RNA  microRNAs 
Protein  - 
Metabolic  - 
Immunological  T-cell and cytokine responses 
Any measurable specific molecular alteration of a cancer cell either at the DNA, RNA, protein, or 
metabolite level can be referred to as a cancer biomarker. The expression of a distinct gene can enable 
its identification in a tissue in which none of the surrounding non-cancerous cells express the specific 
marker. It is difficult to distinguish related disease subtypes that have different clinical outcomes. 
There is therefore a need for more exact molecular biomarkers for use in clinical practice. Recently, 
the  discovery  of  cancer  biomarkers  has  become  a  major  focus  of  cancer  research  and  there  are 
thousands of publications on cancer biomarkers. The ideal biomarkers for cancer have applications in 
determining  predisposition,  early  detection,  assessment  of  prognosis,  and  drug  response.  The 
biomarker that serves as a target for drug development would have an additional advantage. Desirable 
characteristics of molecular markers for cancer are postulated, but no biomarker meets these ideal 
characteristics. Hence, there is an urgent need for cancer biomarkers with more accurate diagnostic 
capability, particularly for early-stage cancer. 
Colorectal cancer (CRC) is the third most common malignancy in the world. In addition, there are 
approximately  1,000,000  new  cases  of  CRC  and  500,000  deaths  associated  with  CRC  each  year. 
Indeed,  CRC  represents  one  of  the  primary  causes  of  cancer  deaths  in  Europe  and  the  United 
States [1]. In Asia, including Japan, CRC is the fourth leading cause of mortality by cancer, and its 
incidence is increasing [2]. CRC develops slowly via a progressive accumulation of genetic mutations. 
Therefore, the risk of recurrence and subsequent death due to CRC is closely related to the stage of the 
disease at the time of the first diagnosis. Recent studies have shown that shifting the detection of the 
disease to an earlier stage via mass screening and intervening at early stage can reduce the risk of death 
from  CRC  [3,4]. These findings  thus  suggest the clinical need for biomarkers for early detection 
of CRC.  
Biomarkers  are  used  as  indicators  of  a  biological  state  of  tissues.  Therefore,  biomarkers  have 
characteristics that enable them to  be objectively  measured and evaluated as  indicators of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. 
One of the key requirements of biomarkers for detecting CRC is that it must allow detection of the Int. J. Mol. Sci. 2010, 11                       
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disease at earlier stages. Such tests using biomarkers should have high sensitivity and specificity, while 
producing a low number of false-negative and false-positive results, to prevent subjecting healthy 
individuals  to  unnecessary  colonoscopies.  Colonoscopy  offers  significant  improvements  in  the 
detection rates for CRC, but the diagnostic value of this is limited in relation to costs, risks, and 
inconvenience  [5].  Non-invasive  biomarkers  have  the  potential  to  greatly  enhance  screening 
acceptance. Several non-invasive tests for detecting CRC are available, of which the fecal occult blood 
test (FOBT) is the most commonly used [6,7]. However, this test lacks sensitivity as well as specificity 
for screening an average risk population. Thus, novel CRC biomarkers that will further enhance the 
detection of the disease and trigger follow-up colonoscopies when necessary should be developed. In 
addition to such detection biomarkers, prognostic markers which can predict the likely course of the 
cancer,  stratification  markers  which  can  predict  the  likely  response  to  drugs  prior  to  beginning 
treatment, and efficacy markers which can monitor the efficacy of drugs treatment may also reduce the 
mortality rate of CRC.  
Table 2. Molecular biomarkers for the detection of CRC. 
Clinical use  Subjects  Types  Potential markers 
In use 
Stool  Protein  Fecal hemoglobin 
Serum 
Protein  CEA 
Carbohydrate  CA19.9 
Clinical 
validation 
Stool 
DNA  K-ras 
DNA  APC 
DNA  L-DNA 
DNA  p53 
Serum  Protein  TIMP-1 
Preclinical 
development 
Serum 
Protein  Spondin-2, DcR3, Trail-R2, Reg IV, MIC1 
Protein  PSME3 
Protein  NNMT 
Protein  CRMP-2 
Protein  SELDI (apolipoprotein C1, C3a-desArg, 1-antitrypsin, transferring) 
Protein  HNP 1-3 
Protein  MIF 
Protein  M-CSF 
Protein  M2-PK 
Protein  Prolactin 
Protein  CCSA-2, -3, -4 
Protein  MMP-9, -7 
Protein  Laminin 
Plasma  DNA  Septin 9 
WBC  DNA  5-gene panel (CDA, BANK1, BCNP1, MS4A1, MGC20553) 
Recent advances in genomics and proteomics have contributed to our understanding of the natural 
history of cancers. Genomic techniques, such as DNA microarray analysis and proteomic methods, for 
example, 2-dimensional electrophoresis and mass spectrometry, are now commonly used to evaluate 
the  expression  profiles  of  genes  and  proteins  in  cancer  cells,  their  surrounding  tissues,  and  body  Int. J. Mol. Sci. 2010, 11                       
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fluids [8]. Identification of genes and/or proteins that are characteristic of the development of cancer 
can potentially uncover biomarkers that will aid in the diagnosis of CRC. In this review, we will focus 
on potential non-biomarkers which have recently been discovered and non-invasive biomarkers which 
are currently being used in clinical settings (Table 2). 
2. Fecal Markers 
2.1. Fecal Hemoglobin  
Stool-based  detection  of  CRC  is  quite  simple,  inexpensive,  and  the  least  invasive  method  of 
screening available [9]. FOBT detecting hemoglobin enzymatically or immunologically is the most 
widely used screening modality for CRC and [10]. Enzymatic FOBT measures the peroxidase-like 
activity of hemoglobin originating from  any source. Therefore,  enzymatic FOBT is  susceptible to 
bleeding from both colorectal and upper gastrointestinal tracts. In addition, the ingestion of certain 
foods (red meats, fruits and vegetables) and medicines (non-steroidal anti-inflammatory drugs) led also 
to  false-positive  results.  Immunological  FOBT  using  antibodies  which  specifically  detect  human 
hemoglobin is not impacted by plant peroxidase in the diet. An important limitation of the FOBT is the 
relatively  poor  sensitivity  at  detecting  early-stage  lesions.  Low  sensitivity  of  the  FOBT  for  the 
detection of colorectal neoplasms is reported to be ~10% of adenomas and 40~85% of CRCs. In fact, 
randomized  clinical  trials  indicated  that  FOBT  is  not  very  reliable  and  that  it  only  reduces  CRC 
mortality by 30% [3,11]. 
2.2. Genes and Epigenetic Markers  
Cryptal cells (colonocytes) are shed into the fecal stream and provide informative materials that can 
be used to detect genes and epigenetic markers in feces [12]. Unlike fecal blood, cryptal cells are shed 
continuously. Furthermore, the shedding of cancer cells from CRC occurs more frequently than from 
normal  colonic  epithelium.  Fecal  cells  including  cancer  cells  can  be  assessed  by  analyzing  DNA 
mutations  for  targets  such  as  K-ras,  p53,  and  adenomatous  polyposis  coli  (APC),  by  analyzing 
epigenetic markers such as microsatellite instability (MSI), or by measuring unfragmented long-form 
DNA (L-DNA).  
K-ras, encoding a Ras family protein, functions as a guanine nucleotide binding protein that is 
involved  in  a  signal  transduction  pathway  including  the  phosphatidylinositol-3-kinase  and 
serine/threonine protein kinase B pathways [13]. K-ras mutations are found in 40–50% of sporadic 
colon cancers and adenomas [14]. In addition, K-ras mutations being present in aberrant crypt foci, 
which are putative pre-cancerous lesions, are reported to be found in 13–95% of CRC [15–18]. Thus, 
K-ras mutations might be an important early event in colorectal carcinogenesis.  
p53  encoding  a  tumor  suppressor  protein  which  regulates  the  expression  of  genes  involved  in 
apoptosis, angiogenesis, the cell cycle and maintenance of the genome [19]. Approximately half of 
human cancers contain mutated p53 genes, and 30–60% of CRCs have mutations in the gene [20]. The 
mutations  depend  on  the  stage,  grade  and  location  of  the  cancer.  The  mutations  appear  to  be  at 
relatively  late  stage  of  colorectal  carcinogenesis,  and  altered  p53  has  only  modest  impact  on  the Int. J. Mol. Sci. 2010, 11                       
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outcome of CRC. Therefore, the relatively low mutation rate of p53 at early-stage limits the use in 
DNA-based detection of CRC.  
APC  protein  is  another  tumor  suppressor  which  assembles  on  a  scaffold  protein,  axin,  with 
-catenin and glycogen synthase kinase 3 to coordinate the regulation of -catenin signaling [21]. 
Inactivation of the APC protein is responsible for both inherited and sporadic types of CRC. Like 
K-ras, APC mutation appears to be an early-genetic event during the progression from adenoma to 
adenocarcinoma, suggesting its potential for use as a screening biomarker. However, unlike K-ras, the 
mutations are distributed throughout the coding region, thereby making it technically difficult and time 
consuming to detect all of the potential mutations during screening for CRC [22,23].  
Microsatellites are stretches of short DNA sequences which contain a motif of 1–5 nucleotides with 
tandem repeats [24]. The most common microsatellite in human DNA is a dinucleotide repeat of 
cytosine and adenine. These tandem repeats occur throughout the human genome. MSI occurs when 
microsatellites undergo changes in length. MSI is observed in approximately 15% of the CRC tumors. 
Tumors with MSI have better prognosis than stage-matched tumors with stable microsatellite [25]. In 
sporadic CRC, MSI most commonly occurs due to epigenetic silencing of the DNA mismatch repair 
gene,  MLH1 [26].  There  are  several  MSI  markers,  among  which  BAT26  is  probably  the  most  
widely used.  
Shedding of cryptal cells is a normal consequence of exfoliation [27]. Untransformed cryptal cells 
are shed continuously from the colonic mucosa. These cells usually undergo apoptosis. Conversely, 
malignant CRC cells shed from tumor mass have a decreased rate of apoptosis relative to normal 
cryptal cells, which facilitate detection of intact genomic DNA (L-DNA) as a potential stool-based 
marker. Boynton [28] amplified six genomic fragments of different length from each of four different 
genetic loci (APC, p53, BRCA1, and BRCA2) using fecal specimens collected from 25 CRC patients 
and 77 controls. In this study, when a positive L-DNA was defined as >18 bands detected from a 
possible 24 bands (4 loci ×  6 fragments), the specificity for CRC detection was 97% and the sensitivity 
was 57%.  
A large population-based study revealed that a fecal DNA panel consisting of 21 mutations (three in 
the K-ras gene, 10 in the APC gene, and eight in the p53 gene; the MSI markers of BAT-26; and 
L-DNA) detects a greater proportion of CRC than FOBT without compromising specificity [29]. In 
addition, the sensitivity of the fecal DNA panel was 52% for invasive CRC and 41% for invasive CRC 
plus adenomas with high-grade dysplasia, whereas that of the FOBT was 13% for the former and 14% 
for the latter. In subjects with negative findings on colonoscopy, the DNA panel had a specificity of 
94%, whereas the FOBT had a specificity of 95%. The results of the study clearly indicate that the 
DNA panel has a greater sensitivity than the FOBT without reduced specificity.  
3. Serum or Blood Markers  
3.1. CEA  
Carcinoembryonic  antigen  (CEA)  is  a  high  molecular  weight  glycoprotein  belonging  to  the 
immunoglobulin superfamily. The carboxy-terminal of CEA contains a hydrophobic region which is 
modified to provide a glycosyl phosphatidylinositol link to the cell membrane. While the presence can Int. J. Mol. Sci. 2010, 11                       
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be determined in biopsy samples, it is usually identified in serum. This protein has been used for many 
years as a biomarker of CRC as well as cancers developing in other tissues [30]. High CEA levels are 
specifically associated with CRC progression, and increased levels of the marker are expected to fall 
following CRC surgery [31]. However, even in the absence of cancer, high CEA levels may also occur 
in  response  to  inflammatory  conditions,  such  as  hepatitis,  inflammatory  bowel  disease  (IBD), 
pancreatitis, and obstructive pulmonary disease. In addition, CEA may not be elevated when CRC is at 
advanced stage. Thus, CEA does not provide sufficient sensitivity and reliability for the early detection 
of CRC. The potential value of the CEA test lies in its use to measure the course of the progression of 
cancer as a prognostic marker. CRC patients with higher CEA levels have poorer prognosis.  
3.2. CA 19-9  
Carbohydrate  antigen  (CA)  19-9,  which  is  the  second  most  investigated  gastrointestinal  tumor 
marker,  is  known  to  be  a  sialylated  Lewis-a  antigen  [32].  CA  19-9  was  originally  defined  by  a 
monoclonal antibody produced by hybridoma prepared from the spleen cells of mice immunized with 
the human CRC cell line, SW 1116. Although CA 19-9 is the best marker available for pancreatic 
adenocarcinoma, CA 19-9 is less sensitive than CEA for CRC and also gives less information than 
CEA [33]. Other carbohydrate antigens, such as CA 50, CA 195, CA 242, CA M26, CA M25, CA 
M43  and  CA  72-4,  have  also  been  evaluated  extensively  [34],  but,  due  to  their  sensitivity,  stage 
dependency and specificity, these antigens are not useful markers for the detection of CRC.  
3.3. Tissue Inhibitor of Metalloproteinase Type 1  
Tissue inhibitor of metalloproteinase type (TIMP)-1 is a multifunctional glycoprotein which inhibits 
most  matrix  metalloproteinases  (MMPs).  The  total  levels  of  TIMP-1  in  patients  with  CRC  are 
significantly greater when compared to that of healthy blood donors who have a very narrow range of 
plasma TIMP-1 levels [35,36]. More importantly, TIMP-1 is capable of being detected at early stages 
of CRC. Conversely, plasma levels of total TIMP-1 in patients with colonic adenomas, IBD or primary 
breast cancer, do not increase [37]. Preoperative TIMP-1 levels were proposed as a stage-independent 
prognostic  biomarker  for  CRC  in  two  independent  studies  [38,39].  The  results  of  these  studies, 
however, indicated that elevation of TIMP-1 was restricted to advanced stages of CRC. Additional 
studies are required to  validate the use of TIMP-1 for both  early diagnosis and evaluation of the 
prognosis of CRC. 
3.4. Five-Serum-Marker Panel (Spondin-2, DcR3, Trail-R2, Reg IV, MIC 1)  
Four serum biomarkers, spondin-2, tumor necrosis factor receptor superfamily member 6B (DcR3), 
TRAIL receptor 2 (TRAIL-R2) and Reg IV were recently evaluated in 600 serum samples. All four 
markers, as well as a fifth marker, macrophage inhibitory cytokine 1 (MIC1), were elevated in patients 
with CRC when compared to normal controls and patients with benign diseases. Additionally, this 
five-serum  biomarker  panel  may  have  better  sensitivity  and  specificity  than  CEA  to  improve  the 
detection rate of early stage CRC. 
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3.5. Nicotinamide N-methyltransferase and Proteasome Activator Complex Subunit 3  
To  analyze  16  matched  CRC  and  adjacent  normal  tissue  samples,  two-dimensional  gel 
electrophoresis and mass spectrometry were used. Then proteins found to be elevated in cancer tissue 
were  further  validated  with  serum  samples.  Elevated  levels  of  nicotinamide  N-methyl-transferase 
(NNMT)  and  proteasome  activator  complex  subunit  3  (PSME3),  which  are  not  predicted  to  be 
secreted, were found in serum from patients with CRC [40,41]. Validation studies using 109 CRC 
samples, 317 healthy control samples, and 87 samples from patients with benign large bowel diseases 
revealed that the diagnostic accuracy of PSME3 was similar to that of CEA, and that NNMT was 
better than CEA at detecting CRC.  
3.6. Collapsin Response Mediator Protein-2  
By  analyzing  the  secretomes  of  21  cancer  cell  lines  derived  from  12  cancer  types,  collapsin 
response mediator protein-2 (CRMP-2) was identified to be a potential CRC biomarker in the serums 
of  201  CRC  patients  and  210  healthy  controls  [42].  The  use  of  CRMP-2  alone  showed  better 
sensitivity, but poorer specificity than CEA. Combined detection using CEA and CRMP-2 however 
produced better sensitivity (77%) and specificity (95%) than detection using either of these markers 
alone (43 and 61% sensitivity, respectively; 87 and 65% specificity, respectively). Thus, CRMP-2 
might be a valuable serum marker when used in combination with CEA.  
4. MicroRNA 
For the past decade, the development of genomic technology has revolutionized modern biological 
research and drug discovery. Functional genomic analyses enable biologists to perform analysis of 
genetic  events  on  a  global  scale  and  they  have  been  widely  used  in  gene  discovery,  biomarker 
determination,  disease  classification,  and  drug  target  identification.  In  this  article,  we  provide  an 
overview of the current and emerging tools involved in genomic studies, including expression arrays, 
microRNA  (miRNA)  arrays,  array  CGH,  ChIP-on-chip,  methylation  arrays,  mutation  analysis, 
genome-wide  association  studies,  proteomic  analysis,  integrated  functional  genomic  analysis  and 
related bioinformatic and biostatistical analyses [43]. 
Post-transcriptional regulation of gene expression by miRNA has recently attracted major interest 
among  cancer  researchers  in  relation  to  its  involvement  in  cancer  development.  More  than  1000 
miRNAs  are  expressed  in  human  cells,  some  tissue  or  cell  type  specific,  others  considered  as 
house-keeping molecules. Functions and direct mRNA targets for some miRNAs have been relatively 
well  studied  over  the  last  years.  Every  miRNA  potentially  regulates  the  expression  of  numerous 
protein-coding genes (tens to hundreds), but it has become increasingly clear that not all miRNAs are 
equally important; diverse high-throughput screenings of various systems have identified a limited 
number  of  key  functional  miRNAs  over  and  over  again.  Particular  miRNAs  emerge  as  principal 
regulators that control major cell functions in various physiological and pathophysiological settings 
[44]. Altered miRNAs are reported in cancers of several tissues, including colon [45–47], liver [48], 
prostate [49],  esophagus [50],  brain  [51],  pancreas  [52],  breast  [53],  and  chronic  degenerative  
disease [54]. Int. J. Mol. Sci. 2010, 11                       
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As  to  CRC,  Dr.  Nakagama’s  group  [55,56]  has  demonstrated  that  Staphylococcal  nuclease 
homology domain 1 (SND1), a component of RISC, is frequently up-regulated in human colon cancers 
and also chemically-induced colon cancers in animals, as well as in preneoplastic lesions of the colon. 
Overexpression of SND1 in colon cancer cells caused down-regulation of APC and activation of the 
Wnt signaling pathway as a consequence, without altering APC mRNA levels. Post-transcriptional 
regulation of gene expression by SND1 was suggested to be mediated by miRNA through the 3'-UTR 
containing the miRNA target sequence. As for the miRNA expression profile, miR-34a was among the 
list of down-regulated miRNA in human colon cancer, suggesting its tumor suppressive role in colon 
carcinogenesis. Expression of miR-34a is tightly regulated by p53, and ectopic expression of miR-34a 
in colon cancer cells causes remarkable reduction of cell proliferation and induces senescence-like 
phenotypes. miR-34a also down-regulates silent information regulator 1 (SIRT1), which is a class III 
histone deacetlylase and known to be a negative regulator of p53 through the modulation of acetylation 
at K382 of p53, and participates in the positive feedback loop of the p53 tumor suppressor network. 
Other investigators [57] also suggested tumor suppressor functions of  miR-34a, in part, through a 
SIRT1-p53  pathway.  Recently,  miRNA  expression  in  CRC  has  been  found  to  be  associated  with 
microsatellite instability (MSI) subgroups, including low MSI and HNPCC-associated cancers [58]. 
Thus, miRNA are potential diagnostic and prognostic markers (Table 3), as well as therapeutic targets 
for CRC.  
Table 3. miRNA related to prognosis of cancer. 
Cancers  miRNA  Authors and Ref. nos. 
Lung cancer 
 
hsa-let-7  [59] 
hsa-let-7a-2 
[60] 
hsa-miR-155 
hsa-miR-196a2  [61] 
hsa-miR-221 
[62] 
hsa-let-7a 
hsa-miR-137 
hsa-miR-372 
hsa-miR-182* 
hsa-miR-21  [63] 
Hepatocellular carcinoma  hsa-miR-125b  [64]  
Breast cancer  hsa-miR-21  [65] 
Gastric cancer  hsa-miR-21  [66] 
Colorectal cancer 
hsa-miR-21  [67] 
hsa-miR-106a  [68] 
Head and neck cancer 
hsa-miR-7d 
[69] 
hsa-miR-205 
Pancreatic cancer  hsa-miR-21  [70] 
Acute myelogenous leukemia  hsa-miR-181 family  [71] 
Chronic lymphocytic leukemia  hsa-miR-1-miR-15a  [72] 
Ovarian cancer  hsa-let-7a-3  [73] 
Esophageal cancer  hsa-miR-103 / 107  [74] 
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5. Other Potential Biomarkers 
Habermann demonstrated that C3a-desArg is present at significantly higher levels in serum from 
patients  with  colorectal  adenomas  and  carcinomas  than  in  serum  from  healthy  individuals  [75]. 
Specifically, in a blinded validation study (n = 59), the use of C3a-desArg alone predicted the presence 
of CRC with a sensitivity of 97% and a specificity of 96%.  
Analyzing  the  protein  profiles  of  colon  cancer  serum  and  protein  profiles  of  CRC  tumors 
demonstrated  that  human  neutrophil  peptides  (HNP)-1,  HNP-2  and  HNP-3,  also  known  as 
a-defensin-1, adefensin-2, and a-defensin-3, are up-regulated in  CRC patients  [76.77].  Indeed,  the 
HNP1-3 level in the serum of 48 CRC patients and 42 normal controls was capable of identifying CRC 
with a sensitivity of 69% and a specificity of 100%.  
The gene expression level of macrophage migration inhibitory factor (MIF) is elevated in CRC 
tissues, suggesting the use of the protein as a potential biomarker for CRC. In an analysis of serum 
samples of 129 patients with colon cancer and 53 healthy control subjects, the serum MIF level was 
found to be significantly increased in patients with CRC [78]. Although the specificity of MIF is not as 
high as that of CEA (90.6% vs. 100.0%), MIF is more sensitive during early cancer detection (47.3% 
vs. 29.5%), which suggests that MIF may be used as a diagnostic marker in CRC. 
The serum levels of both macrophage-colony stimulating factor (M-CSF) and granulocyte-colony 
stimulating factor are significantly higher in CRC patients than in healthy subjects [79,80]. In addition, 
serum levels of M-CSF are more associated with lymph node metastasis than CEA and CA 19-9, 
which suggests that serum M-CSF elevation in CRC patients might help predict the risk of lymph node 
metastasis  of  this  tumor.  M-CSF  may  offer  additional  information  to  that  presented  by  classic 
prognostic factors. 
Prolactin that is synthesized by the anterior pituitary gland is a hormone with multiple biological 
actions and is elevated in patients with CRC. A study that evaluated 47 CRC patients and 51 healthy 
controls revealed that prolactin can predict CRC with a sensitivity and specificity of 77% and 98%, 
respectively [81]. 
M2-pyruvate kinase is an isoform of glycolytic enzyme pyruvate kinase. Although this protein is a 
cytosolic  enzyme,  it  is  liberated  into  circulation  via  an  unknown  mechanism.  It  is  suggested  that 
M2-pyruvate kinase is released into circulation from dying cancer cells. M2-pyruvate may thus be a 
useful marker for the detection of CRC. Two independent studies revealed that the use of M2-pyruvate 
kinase for the detection of CRC has a sensitivity of 48-58% and a specificity of 90–95%. Further, 
when  combined  with  CEA,  the  sensitivity  of  M2-pyruvate  increases  without  decreasing  the 
specificity [82,83]. 
Recent evidence suggests that the assessment of epigenetic events is one of the most promising 
means of identifying biomarker candidates for the early detection of cancer. DNA methylation, in 
which cytosines within the palindromic dinucleotide 5'-CpG-3' sequence are methylated, shapes the 
chromatin structure of DNA according to its functional state [84,85]. The cancer genome is frequently 
characterized by hypermethylation  of specific genes.  Therefore,  epigenomics  AG has  developed a 
blood test for CRC that is based on methylation of SEPT9, NGFR and TMEEF2 [86]. The evaluation 
study of this test, using free-floating DNA extracted from plasma samples of 133 CRC patients and 
179 healthy controls, in the same age range, to determine the methylation levels, using restriction Int. J. Mol. Sci. 2010, 11                       
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enzyme-based qPCR, revealed that the biomarker with the highest performance was SEPT9, which 
was capable of detecting CRC with a specificity and sensitivity of 95% and 52%, respectively, when a 
cutoff of 0.011 g/L of methylated SEPT9 DNA was used. 
Gene expression patterns in the peripheral blood reflect changes that occur within the cells and 
tissues of the body [86]. Han [87] extracted total RNA from the white blood cells of peripheral blood 
and  identified  differentially  regulated  genes  using  a  microarray.  Specifically,  they  used  a  panel 
comprised of five genes including B-cell scaffold protein with ankyrin repeats 1 (BANKI), B-cell 
novel protein 1 (BCNPI), cytidine deaminase (CDS), FERM domain containing 3 (MGC20553), and 
membrane-spanning 4-domains, subfamily A, member 1 (MS4AI), to detect CRC. This test had a 
sensitivity of 88-94% and a specificity of 64–77%. 
Three  proteins,  colon  cancer-specific  antigen  (CCSA)-2,  CCSA-3  and  CCSA-4,  have  shown 
promise as markers for the detection of CRC. Using a cutoff value of 2 g/mL for CCSA-3, both CRC 
and advanced adenoma were detected with 89% sensitivity and 82% specificity [88]. When CCSA-4 
was  used  with  a  cutoff  value  of  0.3  g/mL,  the  sensitivity  and  specificity  was  85%  and  91%, 
respectively. The use of CCSA-2 at a cutoff of 10.8 g/mL had an overall specificity of 78% and 
sensitivity of 97% when used on separate individuals with advanced adenomas and CRC from normal, 
hyperplastic polyp, and adenoma populations [89]. 
Remodeling of the extracellular matrix is important in the development of epithelial malignancies, 
and several extracellular matrix proteins that can be liberated into circulation have been evaluated as 
potential biomarkers. The results of these evaluations have revealed that the serum levels of MMP9 
and MMP7 depend on the presence of CRC [90,91]. In addition, serum laminin and MMP7 can be 
used as independent prognostic markers of CRC [91,92]. 
However, large scale clinical studies are required to refine and validate the diagnostic accuracy of 
the findings mentioned above. 
6. Conclusions  
Cancer biomarkers and characteristics of an ideal biomarker for CRC are discussed in this review, 
as well as technologies for their detection. The focus of this article is on the use of biomarkers for 
anticancer drug development and clinical applications, including determination of prognosis as well as 
monitoring of response to therapy. Types of biomarkers include serum/blood markers, fecal markers 
and miRNA. Currently, the FOBT is the only screening modality for CRC. DNA-based fecal markers 
are  promising  but  are  not  widely  used  in  clinical  settings.  In  addition,  a  lack  of  sensitivity  and 
specificity preclude the use of all existing serum markers for the early detection of CRC. CEA is used 
to monitor therapy in advanced CRC, and the pre-operative level of CEA is used to provide prognostic 
information. However, there is insufficient evidence for routine use of other classic serum markers 
such as carbohydrate antigens and TIMP-1. Therefore, large scale validation studies are required to 
evaluate the potential for the use of biomarkers that have recently been discovered through ‘–omics’ 
technology. Within clinical research, oncology is expected to have the largest gains from biomarkers 
over the next five to ten years. Development of personalized medicine for cancer is closely linked to 
biomarkers, which may serve as the basis for diagnosis, drug discovery and monitoring of diseases. A 
major  challenge  in  development  of  cancer  biomarkers  will  be  the  integration  of  proteomics  with Int. J. Mol. Sci. 2010, 11                       
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genomics and metabolomics data and their functional interpretation in conjunction with clinical data 
and epidemiology [93].  
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